
Insmed D
D
INSM
144.610
USD
5.08
(3.64%)
مغلق
حجم التداول
0
الربح لكل سهم
-2
العائد الربحي
-
P/E
-23
حجم السوق
31,170,959,681
المقالات
العنوان: Insmed
القطاع: Healthcare
الصناعة: Biotechnology
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from theUnited States from the sale of its commercial products.









